Computational Chemistry

Fluorine Fragment Cocktails in Fragment-Based Drug Discovery

Our dedicated products, such as the Fluorine Fragment Cocktail Library and the Fluorine Fragment Library, offer valuable resources and advantages for applying fluorine fragment cocktails to various FBDD projects.

Read more
23 march 2024, 01:16    Svitlana Kondovych Computational Chemistry

Molecular Degraders for Targeted Protein Degradation

Selective targeted protein degradation emerge as a new approach for the development of more effective and precise drugs. At Life Chemicals, we offer tools and services for crafting new molecular glue degraders like PPI inhibitors, PROTACs, and RIBOTACs.

Read more
23 november 2023, 17:47    Svitlana Kondovych Computational Chemistry

Immune Diseases and Reactions in Drug Discovery

Life Chemicals offers a variety of screening libraries of small drug-like molecules for to discovering effective treatments for immune diseases.

Read more
23 october 2023, 16:45    Svitlana Kondovych Computational Chemistry

Signal Pathways in Drug Discovery

Life Chemicals offers small drug-like screening libraries with potential activity against various targets involved in signal cascades aimed for various drug discovery projects: apoptosis signaling, PI3K/Akt/mTOR, RAS/MAPK.

Read more
26 september 2023, 15:06    Svitlana Kondovych Computational Chemistry

Nuclear Receptors in Drug Discovery

Nuclear receptors are a class of proteins that play an essential role in the regulation of gene expression. Nuclear receptor-based drugs hold great potential for the treatment of various diseases. In this connection, Life Chemicals offers a collection of dedicated Screening Libraries.

Read more
14 june 2023, 13:25    Svitlana Kondovych Computational Chemistry
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. By using our website, you accept our conditions of use of cookies to track data and create content (including advertising) based on your interest. Accept